Pharmaceuticals
ESMO 2023 | Ascentage Pharma to Present Results from Two Clinical Studies, including One Oral Presentation, at 2023 ESMO Congress
SUZHOU, China, and ROCKVILLE, Md., Aug. 2, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it is going to release results from two clinic...
2023-08-03 11:43
1374
SK Biopharmaceuticals Assembles 'Board of Prominent Experts' to Boost Growth, Innovation
Renowned oncologist Yung-Jue Bang, M.D., Ph.D., chairs the distinguished 5-member Scientific Advisory Board to further advance SK Biopharmaceuticals as a global big biotech SEOUL, South Korea, Aug. 2, 2023 /PRNewswire/ -- SK Biopharmaceuticals, a global biotech company, announced the formation o...
2023-08-03 07:30
1450
Arbele announces early safety data for novel CDH17xCD3 bispecific T-cell engager at American Society of Clinical Oncology Breakthrough Meeting
SYDNEY, Aug. 2, 2023 /PRNewswire/ -- Arbele, a clinical-stage biotechnology company developing novel immunotherapies targeted for advanced gastrointestinal cancers, presented early safety data from its first-in-class CDH17xCD3 bispecific T-cell engager antibody, ARB202, at the ASCO Breakthrough c...
2023-08-03 07:00
1320
Unlocking the Power of Genetics: Camtech Unveils DNA Self-Test Kits for Holistic Wellness
SINGAPORE, Aug. 2, 2023 /PRNewswire/ -- Camtech Diagnostics, a provider of
innovative healthcare testing solutions, is excited to announce the launch of
its Ideal Health DNA Test
2023-08-02 14:42
1773
Selected for oral presentation! Kelun-Biotech to announce latest clinical study results of SKB264 (MK-2870, TROP2-ADC) for treatment of HR+/HER2- breast cancer at ESMO Congress 2023
CHENGDU, China, Aug. 1, 2023 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990.HK) announced that it will present the data from a Phase I/II clinical trial of the innovative TROP2-ADC (SKB264, MK-2870) jointly developed by Kelun-Biotech and MSD (the t...
2023-08-01 21:07
2589
Peijia Medical Announces First Chinese Patient Implanted with TaurusTrio™ Transcatheter Aortic Valve Replacement System
SUZHOU, China, Aug. 1, 2023 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets, announced onJuly 31, 2023 that the first Chinese patient of the multi-center ...
2023-08-01 20:00
2344
Doer Biologics Announces First Subject Dosed in Phase I 12-Week Multiple-Ascending Dose (MAD) Clinical Trial of DR10624 and Received IND Approval From NMPA
HANGZHOU, China, Aug. 1, 2023 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its first-in-class (FIC), tri-specific agonist targeting...
2023-08-01 17:08
1184
Everest Medicines Announces Completion of Patient Enrollment in Nefecon® China Open Label Extension Study
SHANGHAI, August 1, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today the completion of patient enrollment for theChi...
2023-08-01 08:47
2105
Seegene unveils solutions to popularize molecular diagnostics at 2023 AACC
* Introduced syndromic quantitative PCR assays and a fully automated molecular diagnostic testing system, STARlet AIOS™ * Conducted symposium sessions on the usefulness of PCR testing in diagnosing gastrointestinal diseases * Participated in a presentation event for major Korean in-vitro dia...
2023-08-01 00:00
1472
Fosun Health Capital reached a cooperation agreement with Medicilon to explore innovative drug research and development together
BOSTON, July 31, 2023 /PRNewswire/ -- On July 25, 2023, Fosun Health Capital established by Fosun Pharma (stock code:600196.SH), reached a strategic partnership with Medicilon (stock code: 688202.SH). Meanwhile StarMab Biology (Suzhou) (jointly invested by the innovation drug research fund of Fo...
2023-07-31 20:30
2251
111 to Announce Second Quarter 2023 Unaudited Financial Results on August 24, 2023 - Conference Call to Follow
SHANGHAI, July 31, 2023 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial result...
2023-07-31 17:59
1692
Biosion Announces Phase II Study Start for Anti-TSLP mAb BSI-045B in Atopic Dermatitis (ADAMANT)
NEWARK, N.J. and NANJING, China, July 31, 2023 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global clinical-stage R&D biotechnology company, today announced the phase 2 study initiation for the evaluation of BSI-045B, an anti-TLSP mAb, in the treatment of atopic dermatitis (AD) . "We are pleas...
2023-07-31 17:05
1567
U.S. FDA Accepts Biologics License Application for GC Biopharma's GC5107B (Immune Globulin Intravenous (Human), 10% Liquid)
YONGIN, South Korea, July 31, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a global biopharmaceutical company dedicated to specialty plasma-derived therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's resubmission of the Biologics License App...
2023-07-31 13:20
1708
Transcenta Anti-sclerostin Monoclonal Antibody TST002 (Blosozumab) Received Approval from China CDE to Initiate Phase II Clinical Trial in Patients with Reduced Bone Mineral Density
SUZHOU, China, July 31, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has receiv...
2023-07-31 08:10
1855
Daewoong Pharmaceutical submits a new drug application for Fexuprazan in China challenging the world's largest market for anti-ulcer drugs
– Daewoong Pharmaceutical, "Expecting the smooth approval with the successful phase 3 clinical trial inChina aiming to reach 100 countries by 2027" SEOUL, South Korea, July 31, 2023 /PRNewswire/ -- Daewoong Pharmaceutical's domestically produced drug no. 34 Fexuprazan, a newly developed one for t...
2023-07-31 08:00
2387
Latest Updates of 7 Viva's Portfolio Companies
HONG KONG, July 28, 2023 /PRNewswire/ -- In the face of ever-changing circumstances, technological innovation remains the eternal driving force behind the long-term growth of biopharmaceutical companies. It continuously breathes life into these enterprises, enabling them to successfully transitio...
2023-07-28 19:31
6328
HANQUYOU Marks 3rd Anniversary with Brilliant Achievements
* HANQUYOU is the China-developed biosimilar with the most marketing approvals, covering 41 countries and regions * The launch of HANQUYOU kicks off the competition between Chinese pharmaceutical companies and the world's bio-pharmaceutical companies in biosimilar monoclonal antibodies * He...
2023-07-28 15:53
3544
HANQUYOU Marks 3rd Anniversary with Brilliant Achievements
* HANQUYOU is the China-developed biosimilar with the most marketing approvals, covering 41 countries and regions * The launch of HANQUYOU kicks off the competition between Chinese pharmaceutical companies and the world's bio-pharmaceutical companies in biosimilar monoclonal antibodies * He...
2023-07-28 15:27
2790
Wuan Ankang Hospital's Innovative Tumor Treatment Attracts Many Patients
HANDAN, China, July 28, 2023 /PRNewswire/ -- In Handan City, Hebei Province, China, the Wu'an Ankang Hospital has 35-year of experience with tumor treatment. It has now become a second-class general hospital. The reason it attracts many patients from bothChina and abroad is that they practice hol...
2023-07-28 14:35
1250
GILEAD LAUNCHES GLOBAL ALL4LIVER GRANT PROGRAM TO HELP ACHIEVE THE WORLD HEALTH ORGANIZATION'S GOAL OF VIRAL HEPATITIS ELIMINATION BY 2030
– Gilead expands the ALL4LIVER Grant, Providing Grant Funding to Organizations inAfrica, South America, Asia and Oceania, Europe and North America – – Themed 'Test. Link. Prioritize', the Grant Program will Target Projects Focusing on Viral Hepatitis Elimination by 2030 – SINGAPORE, July 28, ...
2023-07-28 12:00
5471
Week's Top Stories
Most Reposted
ASTON MARTIN ARAMCO FORMULA ONE® TEAM ANNOUNCE PEPPERSTONE AS OFFICAL TRADING PARTNER
[Picked up by 308 media titles]
2025-01-07 09:00
RuggON Unveils VORTEX Vehicle Mount Computer with AI-Enhanced, SATCOM-Ready
[Picked up by 306 media titles]
2025-01-06 21:00
Brewing Connections and Spotlighting Café Culture: MIFB 2025 Hosts MNCC in Collaboration with MSCA
[Picked up by 305 media titles]
2025-01-06 14:00
iWOW Unveils Age-Tech Innovations at CES 2025, Expanding Portfolio of IoT Solutions for Ageing-In-Place
[Picked up by 294 media titles]
2025-01-07 21:18CELEBRATE THE LUNAR NEW YEAR 2025 AT HOIANA RESORT & GOLF, WORLD'S LEADING FULLY INTEGRATED RESORT
[Picked up by 290 media titles]
2025-01-06 19:25
Most Read
Interest-Driven Consumption Sparks ¥ 500B ACG Goods Market, MINISO Rides the Wave
2025-01-03 19:33
10980
